May 10, 2022
Traditional bioanalytical service providers are geared toward analyzing large sets of samples under various regulatory guidelines, such as large nonclinical and clinical studies, which are heavily regulated. This puts a heavy burden on these service providers, creating long lead times, resource constraints and lack of flexibility. Currently, many bioanalytical laboratories report lead times of six to nine months to begin development work. These limited bioanalytical options are causing extensive delays in overall drug development affecting the finances of sponsors.
